FDA's Pe­ter Marks says some sec­ondary can­cer cas­es af­ter CAR-T ther­a­py may be 'causal,' but ben­e­fits still out­weigh risks: #JPM24

The FDA be­lieves that the ben­e­fit of CAR-T ther­a­pies con­tin­ues to out­weigh their risks amid an on­go­ing in­ves­ti­ga­tion on cas­es of sec­ond blood can­cers de­vel­op­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER